中经记者索寒雪北京报道 在未来的临床场景中，可能会出现这样一幕：一方是经验尚浅的年轻主治医生，另一方则是经过海量病 例训练的人工智能系统。当二者针对同一名患者给出不同诊疗建议时，由于信息与权威的不对称，年轻 医生往往面临较大的心理与专业压力，难以直接反驳AI结论。 一位国家卫生健康委基层司相关人士向记者表示，基层医生通常被认为主要擅长常见病、多发病的诊 疗，而AI是通过大规模数据训练形成的智能模型，能够在一定程度上为部分疾病提供相对科学的参考 判断，实现"补位"作用。 该人士进一步表示："AI对于医生而言，是对专业知识乃至跨学科知识的重要补充，这一点对基层医疗 卫生机构的医生来说尤为关键。" 如果医生采纳了AI的错误判断，结果可能被视为技术问题；但若医生否定AI建议却最终判断失误，则 更容易被归因于个人能力不足。这种潜在的责任错位，正成为AI进入医疗场景后亟须回应的现实问 题。 近日，围绕AI诊疗结论的责任归属问题，业内展开了多方讨论。 中国人民大学人口与健康学院党委书记宋月萍在接受《中国经营报》记者采访时表示，智能体的引入， 使医生在医疗行为中同时兼具"委托人"和"代理人"的双重角色，必须通过制度设计明确责 ...

12月12日，2025（第三届）"央广财经年度对话"大型融媒活动在北京顺利举办。本届活动以"启航'十五 五'澎湃新动能"为主题，汇聚了众多专家学者、企业家及金融机构代表，共同围绕产业发展新路径展开 探索。 方舟云康打造的"AI+慢病管理"路径，不仅聚焦于技术层面的创新突破，更注重于可衡量、可复制的商 业价值与社会价值。企业创新推出的"熟人医患"服务模式，以患者首次线下面诊建立的信任为基础，通 过线上平台与AI工具的深度融合，为患者提供长期、持续的慢病管理服务，从而形成了高粘性、高复 购率的用户生态。2025年中期业绩充分印证了这一模式的强大生命力与用户认可度。数据显示，方舟云 康平台付费用户复购率高达85.4%。 在推动自身发展的同时，方舟云康积极践行产业协同，联动行业优质伙伴共同推动互联网医疗高质量发 展。今年，方舟云康与腾讯健康深化合作，联合发布了"AI+慢病管理"解决方案，推动我国慢病管理领 域迈入全新发展阶段。同时，企业还与旺山旺水、诺和诺德、信达生物等多家领先的生物制药企业达成 战略合作，共同打通慢病管理全链路服务体系，为行业智能化、合规化、高效化发展注入新动能。 政策指引发展方向，方舟云康以AI助 ...

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Core Insights - A revolution in health management driven by AI is underway, addressing the challenges posed by an aging population and a high prevalence of chronic diseases in China [1][2] - The online chronic disease management market in China is projected to grow from 45.5 billion yuan in 2023 to 600 billion yuan by 2030, with a compound annual growth rate of 44.5% [1] - Companies are increasingly integrating AI into chronic disease management, with Ark Health achieving a revenue of 1.494 billion yuan in the first half of the year, marking a 12.9% year-on-year increase and a return to profitability [1] Industry Developments - The Chinese government is promoting the use of new technologies in healthcare, aiming to enhance the capabilities and efficiency of grassroots medical services [2] - The rapid development of internet healthcare has significantly improved chronic disease management by breaking geographical barriers and enhancing patient compliance [3] - AI is reshaping the internet healthcare paradigm, with companies focusing on practical solutions to improve healthcare access and quality [4] Technological Innovations - Ark Health has launched an intelligent consultation service that has conducted nearly 400,000 consultations, reducing the average consultation time from 30 minutes to 20 minutes [5] - Companies are developing a range of AI products for healthcare, including AI medication assistants and health managers, creating a comprehensive service ecosystem [5] - The integration of AI in chronic disease management is not limited to the physician's side but also extends to patients and the industry [5] Challenges and Opportunities - Despite the promising outlook for AI in chronic disease management, challenges remain in data privacy, technology implementation, and sustainable business models [6] - The growing demand for weight management solutions in China presents an opportunity for AI applications in managing chronic diseases related to obesity [7] - Companies that understand both healthcare and AI are positioned to drive the core value of medical AI, which is to achieve healthcare accessibility [8]

Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]

Core Insights - Ark Health's release of the "Xing Shi Medical Model" represents a significant advancement in chronic disease management, addressing key industry challenges such as low efficiency and insufficient service precision [1][4] - The model integrates various intelligent agents to form a comprehensive service team, enhancing the overall chronic disease management process [4][6] Company Developments - The "Xing Shi Medical Model" is described as a "super digital brain" that incorporates capabilities like image and voice recognition, natural language understanding, and extensive medical knowledge storage [4] - The model's performance is at the State-of-the-Art (SOTA) level, allowing it to effectively aggregate five intelligent agents for a complete service coverage in chronic disease management [4] - Ark Health has developed five core AI products to support doctors, patients, and industry partners, including AI Medication Finder and AI Health Manager, which enhance the efficiency of internet medical services [4][5] Product Innovations - The "OpenEvidence" tool, powered by the Xing Shi model, serves as a clinical decision support system, providing rapid voice responses to medical inquiries, thus improving usability for busy clinicians [5][6] - The AI Academic Assistant can generate comparative reports on medical guidelines in real-time, showcasing its analytical and reasoning capabilities [5][6] Industry Context - The release aligns with the Chinese government's "Artificial Intelligence +" initiative, which aims to empower various sectors, including healthcare, highlighting the importance of technology in improving public health [6] - Ark Health's commitment to innovation in chronic disease management is evident in its strategic roadmap, which includes the integration of AI technologies and the development of a self-researched medical model by 2025 [6]